Literature DB >> 21437636

Autologous stem cell transplantation in a rare multicentric Castleman disease of the plasma cell variant.

Yuval Tal1, Guy Haber1, Matan J Cohen1, Micci Phillips1, Gail Amir2, Dina Ben-Yehuda3, Arie Ben-Yehuda4.   

Abstract

We present a case of a 52-year-old male who was evaluated due to anorexia, persistent diarrhea, weight loss, and liver enzyme elevations, with no hematologic laboratory abnormalities. Imaging modalities revealed several tissue lesions involving the pancreas, the right kidney, and an axillary lymph node. Diagnosis of Castleman disease was reached only due to the tissue obtained from the lymph node. Chemotherapy and immunosuppression led to a short remission. The patient underwent autologous stem cell transplantation, and has since been in remission. This case demonstrates the cryptogenic and chameleon-like nature of Castleman disease. Challenges in treating Castleman disease patients reflect current limitations and the need for a greater understanding of disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21437636     DOI: 10.1007/s12185-011-0812-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  21 in total

1.  PET/CT findings in a multicentric form of Castleman's disease.

Authors:  Metin Halac; Nurhan Ergul; Sait Sager; Adalet Demir; Nur Buyukpinarbasli; Kerim Sonmezoglu
Journal:  Hell J Nucl Med       Date:  2007 Sep-Dec       Impact factor: 1.102

2.  Focal bone marrow involvement in multicentric castleman disease demonstrated by FDG PET/CT.

Authors:  Celso Dario Ramos; Celso M Massumoto; Maria F Rosa; Mariana F Mazo-Ruiz; Cristina Mitteldorf; Elba C Etchebehere; Allan O Santos; Mariana C Lima; Giovani G Cerri; Edwaldo E Camargo
Journal:  Clin Nucl Med       Date:  2007-04       Impact factor: 7.794

3.  Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena.

Authors:  Enrique M Ocio; Fermin M Sanchez-Guijo; Maria Diez-Campelo; Cristina Castilla; Oscar J Blanco; Dolores Caballero; Jesus F San Miguel
Journal:  Am J Hematol       Date:  2005-04       Impact factor: 10.047

4.  Treatment of multicentric Castleman's disease complicated by the development of non-Hodgkin's lymphoma with high-dose chemotherapy and autologous peripheral stem-cell support.

Authors:  R Advani; R Warnke; S Rosenberg
Journal:  Ann Oncol       Date:  1999-10       Impact factor: 32.976

5.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.

Authors:  J T Beck; S M Hsu; J Wijdenes; R Bataille; B Klein; D Vesole; K Hayden; S Jagannath; B Barlogie
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

6.  The clinical behavior of localized and multicentric Castleman disease.

Authors:  J Herrada; F Cabanillas; L Rice; J Manning; W Pugh
Journal:  Ann Intern Med       Date:  1998-04-15       Impact factor: 25.391

7.  Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome.

Authors:  Apar Kishor Ganti; Iraklis Pipinos; Eliad Culcea; James O Armitage; Stefano Tarantolo
Journal:  Am J Hematol       Date:  2005-07       Impact factor: 10.047

8.  Follicular dendritic sarcoma within a focus of Castleman's disease. Serial FDG PET/CT in the follow up of recurrence with histopathologic confirmation.

Authors:  A Iagaru; C Mari; S Sam Gambhir
Journal:  Rev Esp Med Nucl       Date:  2007 Jan-Feb

9.  Multicentric plasma cell variant of Castleman's disease with cutaneous involvement.

Authors:  Walter M Klein; Adrienne Rencic; Nikhil C Munshi; Carlos H Nousari
Journal:  J Cutan Pathol       Date:  2004-07       Impact factor: 1.587

10.  Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.

Authors:  Hiroshi Kawabata; Naohisa Tomosugi; Junya Kanda; Yasuhiro Tanaka; Kazuyuki Yoshizaki; Takashi Uchiyama
Journal:  Haematologica       Date:  2007-06       Impact factor: 9.941

View more
  7 in total

Review 1.  Transplantation in rare lymphoproliferative and histiocytic disorders.

Authors:  Alexis Cruz-Chacon; John Mathews; Ernesto Ayala
Journal:  Cancer Control       Date:  2014-10       Impact factor: 3.302

2.  The clinical spectrum of Castleman's disease.

Authors:  Angela Dispenzieri; James O Armitage; Matt J Loe; Susan M Geyer; Jake Allred; John K Camoriano; David M Menke; Dennis D Weisenburger; Kay Ristow; Ahmet Dogan; Thomas M Habermann
Journal:  Am J Hematol       Date:  2012-07-13       Impact factor: 10.047

3.  Ascites as a presenting sign of multicentric mixed-type Castleman disease variant of POEMS syndrome.

Authors:  Ganesh Kasinathan; Jameela Sathar
Journal:  Hematol Transfus Cell Ther       Date:  2020-03-20

4.  Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report.

Authors:  Anwarullah Mohammed; Filip Janku; Ming Qi; Razelle Kurzrock
Journal:  J Med Case Rep       Date:  2015-02-28

Review 5.  Update and new approaches in the treatment of Castleman disease.

Authors:  Kah-Lok Chan; Stephen Lade; H Miles Prince; Simon J Harrison
Journal:  J Blood Med       Date:  2016-08-03

6.  International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

Authors:  Frits van Rhee; Peter Voorhees; Angela Dispenzieri; Alexander Fosså; Gordan Srkalovic; Makoto Ide; Nikhil Munshi; Stephen Schey; Matthew Streetly; Sheila K Pierson; Helen L Partridge; Sudipto Mukherjee; Dustin Shilling; Katie Stone; Amy Greenway; Jason Ruth; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Raj Jayanthan; Elaine S Jaffe; Heather Leitch; Naveen Pemmaraju; Amy Chadburn; Megan S Lim; Kojo S Elenitoba-Johnson; Vera Krymskaya; Aaron Goodman; Christian Hoffmann; Pier Luigi Zinzani; Simone Ferrero; Louis Terriou; Yasuharu Sato; David Simpson; Raymond Wong; Jean-Francois Rossi; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Eric Oksenhendler; David C Fajgenbaum
Journal:  Blood       Date:  2018-09-04       Impact factor: 25.476

7.  Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease.

Authors:  Feng Li; Xiaomei Zhang; Yanting Guo; Yuandong Zhu; Yicun Wu; Yun Ling
Journal:  Case Rep Hematol       Date:  2018-01-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.